Previous studies have suggested that genetic variants are associated with prognosis for patients suffering from metastatic colorectal cancer who are treated with oxaliplatin‐based chemotherapy.22 Several reports indicate that SNPs related to chemotherapy resistance exist in p53 signaling pathway genes.23, 24, 25 Most studies have shown that SNPs affect cancer prognosis by altering messenger RNA (mRNA) expression or by combining with microRNA.26 However, the mechanisms whereby SNPs reportedly affect mRNA are inconsistent. The gene discussed is TP53; the disease is metastatic colorectal cancer.